+44 20 8123 2220
info@marketpublishers.com

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020

https://marketpublishers.com/r/G104DA86F92BEN.html
Date: November 2020
Pages: 67
Price: US$ 3,500.00 (Single User License)
ID: G104DA86F92BEN

Abstracts

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020

SUMMARY

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 5, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Osteoporosis and Unspecified Rare Disease.

The latest report Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key

players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)

The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects

The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

+44 20 8123 2220
info@marketpublishers.com

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Global Markets Direct Report Coverage
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
Bainan Biotech ApS
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
Sosei Heptares
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Zealand Pharma AS
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
Product Description

Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
ZP-7570 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
Featured News & Press Releases
Jul 01, 2020: Hanmi Pharm’s short-bowel syndrome drug wins FDA’s rare pediatric disease status
Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland
Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US
Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome
Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome
Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

+44 20 8123 2220
info@marketpublishers.com

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 9 Meters Biopharma Inc, H2 2020
Pipeline by Bainan Biotech ApS, H2 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
Pipeline by Huons Global Co Ltd, H2 2020
Pipeline by OPKO Health Inc, H2 2020
Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
Pipeline by Sosei Heptares, H2 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
Pipeline by VectivBio Holding AG, H2 2020
Pipeline by Zealand Pharma AS, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020
Product link: https://marketpublishers.com/r/G104DA86F92BEN.html
Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G104DA86F92BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970